National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

paricalcitol
A synthetic noncalcemic, nonphosphatemic vitamin D analogue. Paricalcitol binds to the vitamin D receptor and has been shown to reduce parathyroid hormone (PTH) levels. This agent also increases the expression of PTEN ('Phosphatase and Tensin homolog deleted on chromosome Ten'), a tumor-suppressor gene, in leukemic cells and cyclin-dependent kinase inhibitors, resulting in tumor cell apoptosis and tumor cell differentiation into normal phenotypes. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Zemplar



Previous:papaverine, Paraflex, Paraplat, Paraplatin, parathyroid hormone-related protein (1-36)
Next:Parlodel, paroxetine hydrochloride, PARP inhibitor AZD2281, PARP-1 inhibitor AG014699, pasireotide

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov